Secukinumab’s time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study)

Gottlieb, A., Gnanasakthy, A., Strober, B., Zhang, J., & Tran, MH. (2014). Secukinumab’s time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study). Journal of the American Academy of Dermatology, 70(5, Suppl. 1), AB189. https://doi.org/10.1016/j.jaad.2014.01.782

Abstract

Background: Secukinumab (AIN457), a fully human anti–interleukin-17A monoclonal antibody, was evaluated in a phase 3 clinical study at week 12 (vs. placebo) for efficacy and safety in subjects with moderate to severe plaque psoriasis. Time to symptom response was evaluated using the Psoriasis Symptom Diary (PSD), which measures psoriasis-related characteristics subjects have reported as important and relevant to their disease and treatment.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Internalizing and externalizing subtypes of alcohol misuse and their relation to drinking motives
Article

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers
Article

Far-right and Jihadi terrorism within the United States
Article

What's in a name? A data-driven method to identify optimal psychotherapy classifications to advance treatment research on co-occurring PTSD and substance use disorders